Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes treatment. This compound demonstrates superior efficacy in glucose control and weight reduction compared to selective GLP-1 receptor agonists like semaglutide.
The molecular structure of Tirzepatide features a lysine side chain with PEG modification, enhancing water solubility while maintaining biological activity. Clinical trials have shown significant weight loss results, with participants achieving 15-20.9% reduction in body weight over 72 weeks at different dosage levels (5mg, 10mg, and 15mg).
As a research chemical, Tirzepatide offers scientists new opportunities to study dual receptor agonism mechanisms. The compound has received FDA Fast Track designation for obesity treatment research, highlighting its potential in metabolic disorder studies.
Our pharmaceutical grade Tirzepatide meets strict quality standards with 99% purity, making it ideal for laboratory research purposes. The product is supplied in vials with precise labeling and batch documentation for traceability.
For researchers looking for semaglutide uk buy alternatives, Tirzepatide presents an advanced option with dual mechanism action. Its structural similarity to semaglutide uk buy compounds allows for comparative studies while offering unique pharmacological properties.
Note: This product is intended for research use only, not for human consumption. Proper handling procedures should be followed by qualified researchers in controlled laboratory environments.